Differentiation between low- and high-efficacy CB1 receptor agonists using a drug discrimination protocol for rats (original) (raw)
Abadji V, Lin S, Taha G, Griffin G, Stevenson LA, Pertwee RG, Makriyannis A (1994) (R)-Methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J Med Chem 37:1889–1893 ArticleCASPubMed Google Scholar
Adams IB, Compton DR, Martin BR (1998) Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. J Pharmacol Exp Ther 284:1209–1217 CASPubMed Google Scholar
Alici T, Appel JB (2004) Increasing the selectivity of the discriminative stimulus effects of delta-9-tetrahydrocannabinol: complete substitution with methanandamide. Pharmacol Biochem Behav 79:431–437 ArticleCASPubMed Google Scholar
Bergman J, France CP, Holtzman SG, Katz JL, Koek W, Stephens DN (2000) Agonist efficacy, drug dependence, and medications development: preclinical evaluation of opioid, dopaminergic, and GABAA-ergic ligands. Psychopharmacol (Berl) 153:67–84 ArticleCAS Google Scholar
Bosier B, Muccioli GG, Hermans E, Lambert DM (2010) Functionally selective cannabinoid receptor signalling: therapeutic implications and opportunities. Biochem Pharmacol 80:1–12 ArticleCASPubMed Google Scholar
Breivogel CS, Childers SR (2000) Cannabinoid agonist signal transduction in rat brain: comparison of cannabinoid agonists in receptor binding, G-protein activation, and adenylyl cyclase inhibition. J Pharmacol Exp Ther 295:328–336 CASPubMed Google Scholar
Breivogel CS, Selley DE, Childers SR (1998) Cannabinoid receptor agonist efficacy for stimulating [35 _S_]GTPgammaS binding to rat cerebellar membranes correlates with agonist-induced decreases in GDP affinity. J Biol Chem 273:16865–16873 ArticleCASPubMed Google Scholar
Burkey RT, Nation JR (1997) (R)-Methanandamide, but not anandamide, substitutes for Δ9-THC in a drug-discrimination procedure. Exp Clin Psychopharmacol 5:195–202 ArticleCASPubMed Google Scholar
Carriero D, Aberman J, Lin SY, Hill A, Makriyannis A, Salamone JD (1998) A detailed characterization of the effects of four cannabinoid agonists on operant lever pressing. Psychopharmacol (Berl) 137:147–156 ArticleCAS Google Scholar
Childers SR (2006) Activation of G-proteins in brain by endogenous and exogenous cannabinoids. AAPS J 8:E112–E117 ArticleCASPubMed Google Scholar
Compton DR, Gold LH, Ward SJ, Balster RL, Martin BR (1992) Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from Δ9-tetrahydrocannabinol. J Pharmacol Exp Ther 263:1118–1126 CASPubMed Google Scholar
De Vry J, Jentzsch KR (2002) Discriminative stimulus effects of BAY 38–7271, a novel cannabinoid receptor agonist. Eur J Pharmacol 457:147–152 ArticlePubMed Google Scholar
De Vry J, Jentzsch KR (2003) Intrinsic activity estimation of cannabinoid CB1 receptor ligands in a drug discrimination paradigm. Behav Pharmacol 14:471–476 PubMed Google Scholar
Extance K, Goudie AJ (1981) Inter-animal olfactory cues in operant drug discrimination procedures in rats. Psychopharmacol (Berl) 73:363–371 ArticleCAS Google Scholar
Falenski KW, Thorpe AJ, Schlosburg JE, Cravatt BF, Abdullah RA, Smith TH, Selley DE, Lichtman AH, Sim-Selley LJ, Long JZ, Nomura DK, Vann RE, Walentiny DM, Booker L, Jin X, Burston JJ, Wiley JL (2010) FAAH(−/−) mice display differential tolerance, dependence, and cannabinoid receptor adaptation after Δ9-tetrahydrocannabinol and anandamide administration: dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. Neuropsychopharmacology 35:1775–1787 CASPubMed Google Scholar
Gifford AN, Bruneus M, Gatley SJ, Lan R, Makriyannis A, Volkow ND (1999) Large receptor reserve for cannabinoid actions in the central nervous system. J Pharmacol Exp Ther 288:478–483 CASPubMed Google Scholar
Giuffrida A, McMahon LR (2010) In vivo pharmacology of endocannabinoids and their metabolic inhibitors: therapeutic implications in Parkinson's disease and abuse liability. Prostaglandins Lipid Mediat 91:90–103 ArticleCAS Google Scholar
Glennon RA, Young R (2011a) Drug discrimination: practical considerations. In: Glennon RA, Young R (eds) Drug discrimination: applications to medicinal chemistry and drug studies. Wiley, Hoboken, pp 41–128 Chapter Google Scholar
Glennon RA, Young R (2011b) Role of stereochemistry in drug discrimination studies. In: Glennon RA, Young R (eds) Drug discrimination: applications to medicinal chemistry and drug studies. Wiley, Hoboken, pp 129–161 Chapter Google Scholar
Hruba L, Ginsburg BC, McMahon LR (2012) Apparent inverse relationship between cannabinoid agonist efficacy and tolerance/cross-tolerance produced by Δ9-tetrahydrocannabinol treatment in rhesus monkeys. J Pharmacol Exp Ther 342:843–849 ArticleCASPubMed Google Scholar
Järbe TUC (1986) State-dependent learning and drug discriminative control of behaviour: an overview. Acta Neurol Scand Suppl 109:37–59 ArticlePubMed Google Scholar
Järbe TUC (1989) Discrimination learning with drug stimuli: methods and applications. In: Boulten AA, Baker GB, Greenshaw AJ (eds) Neuromethods, vol 13, Psychopharmacology. Humana, Clifton, pp 513–563 Google Scholar
Järbe TUC (2011) Perceptual drug discriminative aspects of the endocannabinoid signaling system in animals and man. In: Glennon RA, Young R (eds) Drug discrimination: applications to medicinal chemistry and drug studies. Wiley, Hoboken, pp 241–285 Chapter Google Scholar
Järbe TUC, Gifford RS (2013) “Herbal incense”: designer drug blends as cannabimimetics and their assessment by drug discrimination and other in vivo bioassays. Life Sci. doi:10.1016/j.lfs.2013.07.011 PubMed Google Scholar
Järbe TUC, Swedberg MDB (1982) A conceptualization of drug discrimination learning. In: Colpaert FC, Slangen JL (eds) Drug discrimination: application in CNS pharmacology. Elsevier/North-Holland Biomed, Amsterdam, pp 327–341 Google Scholar
Järbe TUC, Lamb RJ, Makriyannis A, Lin S, Goutopoulos A (1998a) Δ9-THC training dose as a determinant for (R)-methanandamide generalization in rats. Psychopharmacol (Berl) 140:519–522 Article Google Scholar
Järbe TUC, Sheppard R, Lamb RJ, Makriyannis A, Lin S, Goutopoulos A (1998b) Effects of delta-9-tetrahydrocannabinol and (R)-methanandamide on open-field behavior in rats. Behav Pharmacol 9:169–174 PubMed Google Scholar
Järbe TUC, Lamb RJ, Lin S, Makriyannis A (2000) Δ9-THC training dose as a determinant for (R)-methanandamide generalization in rats: a systematic replication. Behav Pharmacol 11:81–86 ArticlePubMed Google Scholar
Järbe TUC, Lamb RJ, Lin S, Makriyannis A (2001) (R)-methanandamide and Δ9-THC as discriminative stimuli in rats: tests with the cannabinoid antagonist SR-141716 and the endogenous ligand anandamide. Psychopharmacol (Berl) 156:369–380 Article Google Scholar
Järbe TUC, Andrzejewski ME, DiPatrizio NV (2002) Interactions between the CB1 receptor agonist delta-9-THC and the CB1 receptor antagonist SR-141716 in rats: open-field revisited. Pharmacol Biochem Behav 73:911–919 ArticlePubMed Google Scholar
Järbe TUC, DiPatrizio NV, Li C, Makriyannis A (2003) The cannabinoid receptor antagonist SR-141716 does not readily antagonize open-field effects induced by the cannabinoid receptor agonist (R)-methanandamide in rats. Pharmacol Biochem Behav 75:809–821 ArticlePubMed Google Scholar
Järbe TUC, Lamb RJ, Liu Q, Makriyannis A (2006) Discriminative stimulus functions of AM-1346, a CB1R selective anandamide analog, in rats trained with Δ9-THC or (R)-methanandamide (AM-356). Psychopharmacol (Berl) 188:315–323 Article Google Scholar
Järbe TUC, Li C, Vadivel SK, Makriyannis A (2008) Discriminative stimulus effects of the cannabinoid CB1 receptor antagonist rimonabant in rats. Psychopharmacol (Berl) 198:467–478 Article Google Scholar
Järbe TUC, Li C, Liu Q, Makriyannis A (2009) Discriminative stimulus functions in rats of AM1346, a high-affinity CB1R selective anandamide analog. Psychopharmacol (Berl) 203:229–239 Article Google Scholar
Järbe TUC, Li C, Vadivel SK, Makriyannis A (2010) Discriminative stimulus functions of methanandamide and Δ9-THC in rats: tests with aminoalkylindoles (WIN55,212-2 and AM678) and ethanol. Psychopharmacol (Berl) 208:87–98 Article Google Scholar
Järbe TUC, Deng H, Vadivel SK, Makriyannis A (2011a) Cannabinergic aminoalkylindoles, including AM678 = JWH018 found in ‘Spice’, examined using drug (Δ9-THC) discrimination for rats. Behav Pharmacol 22:498–507 ArticlePubMed CentralPubMed Google Scholar
Järbe TUC, Lemay BJ, Vemuri VK, Vadivel SK, Zvonok A, Makriyannis A (2011b) Central mediation and differential blockade by cannabinergics of the discriminative stimulus effects of the cannabinoid CB(1) receptor antagonist rimonabant in rats. Psychopharmacol (Berl) 216:355–365 Article Google Scholar
Järbe TUC, Tai S, Lemay BJ, Nikas SP, Shukla VG, Zvonok A, Makriyannis A (2012) AM2389, a high-affinity, in vivo potent CB(1)-receptor-selective cannabinergic ligand as evidenced by drug discrimination in rats and hypothermia testing in mice. Psychopharmacol (Berl) 220:417–426 Article Google Scholar
Kangas BD, Delatte MS, Vemuri VK, Thakur GA, Nikas S, Makriyannis A, Bergman J (2013) Cannabinoid discrimination and antagonism by CB1 neutral and inverse agonist antagonists. J Pharmacol Exp Ther 344(3):561–567 ArticleCASPubMed Google Scholar
Kenakin TP (1993) Pharmacological analysis of drug–receptor interaction, 2nd edn. Raven Press, New York Google Scholar
Kenakin T (2011) Functional selectivity and biased receptor signaling. J Pharmacol Exp Ther 336:296–302 ArticleCASPubMed Google Scholar
Lan R, Liu Q, Fan P, Lin S, Fernando SR, McCallion D, Pertwee R, Makriyannis A (1999) Structure–activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J Med Chem 42:769–776 ArticleCASPubMed Google Scholar
Lelas S, Spealman RD, Rowlett JK (2000) Using behavior to elucidate receptor mechanisms: a review of the discriminative stimulus effects of benzodiazepines. Exp Clin Psychopharmacol 8:294–311 ArticleCASPubMed Google Scholar
Li J-X, Gerak LR, France CP (2011) Drug discrimination studies in monkeys: drug dependence and withdrawal. In: Glennon RA, Young R (eds) Drug discrimination: applications to medicinal chemistry and drug studies. Wiley, Hoboken, pp 417–430 Chapter Google Scholar
Long JZ, Nomura DK, Vann RE, Walentiny DM, Booker L, Jin X, Burston JJ, Sim-Selley LJ, Lichtman AH, Wiley JL, Cravatt BF (2009) Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. Proc Natl Acad Sci U S A 106:20270–20275 ArticleCASPubMed CentralPubMed Google Scholar
Mackie K (2008) Cannabinoid receptors: where they are and what they do. J Neuroendocrinol 20(Suppl 1):10–14 ArticleCASPubMed Google Scholar
McMahon LR (2006) Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Δ9-tetrahydrocannabinol. J Pharmacol Exp Ther 319:1211–1218 ArticleCASPubMed Google Scholar
McMahon LR (2011) Chronic Δ9-tetrahydrocannabinol treatment in rhesus monkeys: differential tolerance and cross-tolerance among cannabinoids. Br J Pharmacol 162:1060–1073 ArticleCASPubMed Google Scholar
McMahon LR, Ginsburg BC, Lamb RJ (2008) Cannabinoid agonists differentially substitute for the discriminative stimulus effects of Δ9-tetrahydrocannabinol in C57BL/6J mice. Psychopharmacol (Berl) 198:487–495 ArticleCAS Google Scholar
National Institutes of Health (1996) Principles of Animal Laboratory Care. National Academy Press Washington, D.C.
Overton DA (1988) Similarities and differences between behavioral control by drug-produced stimuli and by sensory stimuli. In: Colpaert FC, Balster RL (eds) Transduction mechanisms of drug stimuli. Springer, Berlin, pp 176–198 Chapter Google Scholar
Paronis CA, Nikas SP, Shukla VG, Makriyannis A (2012) Δ9-Tetrahydrocannabinol acts as a partial agonist/antagonist in mice. Behav Pharmacol 23:802–805 ArticleCASPubMed CentralPubMed Google Scholar
Pério A, Rinaldi-Carmona M, Maruani J, Barth F, Le Fur G, Soubrié P (1996) Central mediation of the cannabinoid cue: activity of a selective CB1 antagonist, SR 141716A. Behav Pharmacol 7:65–71 ArticlePubMed Google Scholar
Picker MJ, Dykstra LA (1989) Discriminative stimulus effects of mu and kappa opioids in the pigeon: analysis of the effects of full and partial mu and kappa agonists. J Pharmacol Exp Ther 249:557–566 CASPubMed Google Scholar
Schlosburg JE, Blankman JL, Long JZ, Nomura DK, Pan B, Kinsey SG, Nguyen PT, Ramesh D, Booker L, Burston JJ, Thomas EA, Selley DE, Sim-Selley LJ, Liu QS, Lichtman AH, Cravatt BF (2010) Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nat Neurosci 13:1113–1119 ArticleCASPubMed CentralPubMed Google Scholar
Singh H, Schulze DR, McMahon LR (2011) Tolerance and cross-tolerance to cannabinoids in mice: schedule-controlled responding and hypothermia. Psychopharmacol (Berl) 215:665–675 ArticleCAS Google Scholar
Sink KS, McLaughlin PJ, Wood JA, Brown C, Fan P, Vemuri VK, Peng Y, Olszewska T, Thakur GA, Makriyannis A, Parker LA, Salamone JD (2008) The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats. Neuropsychopharmacology 33:946–955 ArticleCASPubMed CentralPubMed Google Scholar
Solinas M, Tanda G, Justinova Z, Wertheim CE, Yasar S, Piomelli D, Vadivel SK, Makriyannis A, Goldberg SR (2007) The endogenous cannabinoid anandamide produces Δ9-tetrahydrocannabinol-like discriminative and neurochemical effects that are enhanced by inhibition of fatty acid amide hydrolase but not by inhibition of anandamide transport. J Pharmacol Exp Ther 321:370–380 ArticleCASPubMed Google Scholar
Stewart JL, McMahon LR (2010) Rimonabant-induced Δ9-tetrahydrocannabinol withdrawal in rhesus monkeys: discriminative stimulus effects and other withdrawal signs. J Pharmacol Exp Ther 334:347–356 ArticleCASPubMed Google Scholar
Stolerman IP (2011) The discrimination of drug mixtures. In: Glennon RA, Young R (eds) Drug discrimination: applications to medicinal chemistry and drug studies. Wiley, Hoboken, pp 323–359 Chapter Google Scholar
Stolerman IP, Childs E, Ford MM, Grant KA (2011) Role of training dose in drug discrimination: a review. Behav Pharmacol 22:415–429 ArticlePubMed CentralPubMed Google Scholar
Tai S, Järbe TUC, LeMay B, Nikas SP, Makriyannis A (2008) In vivo characterization of AM-2389, a potent CB1R selective agonist. International Cannabinoid Research Society (ICRS), Burlington
Thakur GA, Nikas SP, Li C, Makriyannis A (2005) Structural requirements for cannabinoid receptor probes. In: Pertwee RG (ed) Handbook of experimental pharmacology. Springer, New York, pp 210–246 Google Scholar
Walker EA, Young AM (1993) Discriminative-stimulus effects of the low efficacy mu agonist nalbuphine. J Pharmacol Exp Ther 267:322–330 CASPubMed Google Scholar
Walker EA, Young AM (2002) Clocinnamox distinguishes opioid agonists according to relative efficacy in normal and morphine-treated rats trained to discriminate morphine. J Pharmacol Exp Ther 302:101–110 ArticleCASPubMed Google Scholar
Wiley JL, Barrett RL, Lowe J, Balster RL, Martin BR (1995) Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoids in rats. Neuropharmacology 34:669–676 ArticleCASPubMed Google Scholar
Wiley JL, Matthew Walentiny D, Vann RE, Baskfield CY (2011) Dissimilar cannabinoid substitution patterns in mice trained to discriminate Δ9-tetrahydrocannabinol or methanandamide from vehicle. Behav Pharmacol 22:480–488 ArticleCASPubMed CentralPubMed Google Scholar
Wolff MC, Leander JD (1997) Differentiation of 5-HT1A receptor ligands by drug discrimination. Eur J Pharmacol 333:113–122 ArticleCASPubMed Google Scholar
Woolverton WL, Schuster CR (1983) Behavioral and pharmacological aspects of opioid dependence: mixed agonist-antagonists. Pharmacol Rev 35:33–52 CASPubMed Google Scholar